AzTrials
AzTrials

Relapsed Adult ALLNCT06581081

Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia

A study testing Senl_B19 autologous CAR-T (S1904) treatment in people with Relapsed Adult ALL and B-cell Acute Lymphoblastic Leukemia, run by Peking University People's Hospital at 1 site in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Targeted CD19 CAR-T cell immunotherapy is an effective means of treating R/R B-ALL. Read more about this study

Who is it for?
Ages 12 to 65 years
What is being tested?
Senl_B19 autologous CAR-T (S1904) treatment
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
130 participants
Where
1 siteChina
Study dates
1 Oct 2024to 31 Aug 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 65 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • The subject or guardian understands and voluntarily signs the Informed Consent Form (ICF);
  • Male or female, aged 12-65 years (including the cutoff value) when signing the informed consent form;
  • Expected survival period is not less than 12 weeks;
  • ECOG physical performance score is 0-1 when signing the ICF;
  • The subject must be diagnosed with relapsed/refractory B-cell acute lymphoblastic leukemia when signing the ICF, and at least one of the following must be met:
  • Relapse: including relapse within 12 months after the first remission, 2 or more relapses;
Show all 17Show fewer
  • Refractory: including primary refractory, failure to achieve remission after at least 2 courses of induction therapy, or failure to achieve remission after at least 1 course of salvage therapy after the first relapse.
  • For patients with Philadelphia chromosome-positive ALL (Ph+ ALL), in addition to meeting the above relapse or refractory criteria, they should have failed at least two tyrosine kinase inhibitor (TKI) treatments (except for those with T315I mutations), or be unable to tolerate TKI treatment, or have contraindications to TKI treatment;
  • Bone marrow morphology examination at screening showed that the proportion of primitive immature lymphocytes in the bone marrow was >5%;
  • Tumor cells in the bone marrow or peripheral blood were CD19 positive by flow cytometry at screening;
  • Major organ functions must meet the following requirements:
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×upper limit of normal (ULN);
  • Total bilirubin ≤2×ULN;
  • Serum creatinine clearance of adult subjects ≥60 mL/min (Cockcroft-Gault formula) or creatinine ≤1.5×upper limit of normal (ULN);
  • Serum creatinine for children: no more than 1.2 mg/dL for 10 to 13 years old, no more than 1.5 mg/dL for males aged 13 to 16 years old, no more than 1.4 mg/dL for females aged 13 years and above, and no more than 1.7 mg/dL for males aged 16 years and above.
  • Blood oxygen saturation>92%;
  • Males and females of childbearing age with fertility must agree to use effective contraceptive measures from the signing of the informed consent form until 2 years after the use of the study drug. Females of childbearing age include premenopausal women and women within 2 years after menopause. The blood pregnancy test of females of childbearing age must be negative at the time of screening.

Who cannot join

  • Isolated extramedullary relapse;
  • Burkitt's lymphoma/leukemia;
  • Previous history of CNS disease, including but not limited to epilepsy, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, neuropathy (except inactive CNS leukemia);
  • Previous hematopoietic stem cell transplantation;
  • History of autoimmune disease requiring systemic immunosuppressive drug treatment within 2 years before signing the ICF (including but not limited to Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, inflammatory bowel disease, vasculitis, psoriasis);
  • Any uncontrolled active infection at the time of signing the ICF or within 4 weeks before apheresis, requiring antibiotic, antiviral or antifungal treatment;
Show all 35Show fewer
  • Previous cell therapy targeting CD19 (autologous or allogeneic);
  • Received CAR-T therapy or other cell/gene therapy before screening;
  • Those who tested positive for hepatitis B surface antigen (HBsAg) during screening need to be excluded; if HBsAg is negative but hepatitis B core antibody (HBcAb) is positive, those with peripheral blood hepatitis B virus (HBV) DNA above the detection limit need to be excluded; those who tested positive for hepatitis C virus (HCV) antibody and HCV RNA need to be excluded; those who tested positive for human immunodeficiency virus (HIV) antibody; those who tested positive for cytomegalovirus (CMV) DNA; those who tested positive for human lymphotropic herpes virus (EBV) DNA; those who tested positive for both Treponema pallidum-specific and non-specific antibodies;
  • Clinically significant cardiovascular disease, including any of the following:
  • QTc interval ≥470 ms after heart rate correction (QTc interval calculated by Fridericia formula);
  • New York Heart Association (NYHA) grade II or above heart failure;
  • Unstable angina or acute myocardial infarction within 6 months before signing the ICF;
  • Left ventricular ejection fraction (LVEF) < 50%;
  • Poorly controlled hypertension (systolic blood pressure ≥ 150 mm Hg and/or diastolic blood pressure ≥ 95 mm Hg);
  • Arrhythmias with clinical significance or requiring antiarrhythmic treatment (such as sustained ventricular tachycardia, ventricular fibrillation, torsade de pointes tachycardia and complete left bundle branch block, etc.);
  • Allergic to any drug component to be used in this study, including but not limited to S1904, clearing drugs (cyclophosphamide, fludarabine), etc.;
  • Received any study drug treatment or other systemic anti-tumor treatment within 4 weeks before apheresis (or 5 half-lives of the drug, whichever is more appropriate as determined by the researcher);
  • Received extensive radiotherapy within 4 weeks before signing the ICF, except for local radiotherapy of non-target lesions for symptom relief within 2 weeks before signing the ICF or expected during the study period;
  • At the time of signing the ICF, except for alopecia and pigmentation, the toxicity caused by previous anti-tumor treatment has not recovered to grade 1 or baseline level (according to NCI-CTCAE version 5.0);
  • Patients who need to receive systemic corticosteroids (dose equivalent to or higher than 10 mg/day of prednisone) or other immunosuppressive drugs within 2 weeks before signing the ICF or within 2 weeks before apheresis or during the study, except for the following:
  • Intranasal, inhaled, local steroids or local steroid injections (such as intra-articular injections), or
  • Systemic corticosteroid treatment not exceeding 10 mg/day of prednisone or its equivalent physiological dose, or
  • Steroids as a preventive medication for allergic reactions (such as pretreatment before computed tomography [CT]), or
  • Used for symptomatic treatment of adverse reactions after reinfusion;
  • Subjects who have undergone major surgery (except routine biopsy) within 4 weeks before signing the ICF, or are expected to undergo major surgery during the study;
  • Subjects with a history of active tuberculosis infection within 1 year before signing the ICF (except for subjects with a history of active tuberculosis infection more than 1 year ago who are judged by the investigator to have no evidence of active tuberculosis);
  • Subjects with clinically significant thyroid dysfunction as judged by the investigator;
  • Subjects with or with a history of interstitial lung disease or interstitial pneumonia;
  • Subjects with a history of other primary malignant tumors within 5 years before signing the ICF, except for the following:
  • Cervical carcinoma in situ that has been fully treated and cured;
  • Localized basal cell carcinoma or squamous cell carcinoma of the skin;
  • Subjects who have received attenuated/inactivated vaccines within 4 weeks before signing the ICF, or subjects who are planned to receive attenuated/inactivated vaccines during the screening period;
  • The researcher believes that the subject's complications or other conditions may affect compliance with the protocol or may be unsuitable for participation in this study;
  • Pregnancy or lactation.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Yu Wang, MD contact

86-88326666

ywyw3172@sina.com

China1 site, 1 recruiting

  • Peking University People'S Hospital

    Beijing, Beijing Municipality, 100044

    yu wang, 861088326001, ywyw3172@sina.com

    xiaojun huang

    Recruiting

Other trials in China

About this study

Official title: Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia, a Prospective, Open, Multicenter, Randomized, Control Study (COMPLETE Study)

Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Targeted CD19 CAR-T cell immunotherapy is an effective means of treating R/R B-ALL. Several clinical studies have shown that its remission rate for R/R B-ALL can reach 68-93%. However, long-term follow-up found that the remission time after CD19 CAR-T treatment is short and the relapse rate is high. Therefore, how to ensure the long-term survival of R/R B-ALL patients after remission by CAR-T therapy is an urgent problem to be solved. Some studies have shown that timely bridging allo-HSCT after CAR-T treatment can overcome the risk of relapse and further improve the long-term survival of patients. However, there is currently no randomized controlled study on whether to bridge transplantation after CAR-T. The purpose of this study is to evaluate the efficacy and safety of S1904 in the treatment of relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia with or without bridging to allogeneic hematopoietic stem cell transplantation after remission.

Being tested
Senl_B19 autologous CAR-T (S1904) treatment
Medical subject headings
Precursor Cell Lymphoblastic Leukemia-Lymphoma, Burkitt Lymphoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Senl_B19 autologous CAR-T (S1904) treatmentBiological

    Subjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment.

Study groups in NCT06581081
Study groupRoleWhat they receive
Bridging to allo-HSCTExperimentalSubjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment. If the subject achieves bone marrow leukemia-free state (MLFS) and minimal residual disease (MRD) negative within 12 weeks after S1904 infusion, they will be randomly assigned to the bridging transplant group and the non-bridging transplant group at a ratio of 2:1.
Receives: Biological: Senl_B19 autologous CAR-T (S1904) treatment
No bridging to allo-HSCTOtherSubjects enrolled in this study will first receive Senl_B19 autologous CAR-T (S1904) treatment. If the subject achieves bone marrow leukemia-free state (MLFS) and minimal residual disease (MRD) negative within 12 weeks after S1904 infusion, they will be randomly assigned to the bridging transplant group and the non-bridging transplant group at a ratio of 2:1.
Receives: Biological: Senl_B19 autologous CAR-T (S1904) treatment

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 2-year event-free survival after randomization

    The time from randomization to MRD positive or relapse or death due to non-relapse causes (whichever occurs first)

    Measured: Participants will be followed for an expected average of 2 years

Secondary outcomes (3)

  1. 2-year relapse-free survival after randomization

    Time from randomization to relapse or death from any cause (whichever occurs first)

    Measured: Participants will be followed for an expected average of 2 years

  2. Cumulative incidence of relapse

    Time from randomization to relapse

    Measured: Participants will be followed for an expected average of 2 years

  3. 2-year overall survival after randomization

    Time from randomization to death from any cause

    Measured: Participants will be followed for an expected average of 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Aug 2024
  2. Study start1 Oct 2024
  3. Primary completion31 Aug 2027 (estimated)
  4. Study completion31 Aug 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
130 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06581081
Sponsor's protocol ID
COMPLETE
Status last verified
Mar 2025
First submitted
29 Aug 2024
Last updated
12 Mar 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Senl_B19 autologous CAR-T (S1904) treatment in people with Relapsed Adult ALL and B-cell Acute Lymphoblastic Leukemia, run by Peking University People's Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 17 inclusion and 35 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 12 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Yu Wang, MD (86-88326666, ywyw3172@sina.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

2-year event-free survival after randomization (time frame: Participants will be followed for an expected average of 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06581081.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Mar 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in